Limits...
Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes.

Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M - Arch Med Sci (2010)

Bottom Line: In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated.No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern.Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Introduction: The aim of this study was to evaluate the effects and mechanisms of Setarud (IMOD™) as a multi-herbal medicinal formula on a mouse model of type 1 diabetes. METERIAL AND METHODS: Autoimmune diabetes was induced by multiple low-dose intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) for five consecutive days. IMOD™ was administered at an effective dose of 20 mg/kg/day for 21 days. After 21 days of treatment, the pancreases of the animals were separated and homogenized. In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated. Glucose changes were tested in the blood. Microscopic changes in the pancreas were followed by histological examinations.

Results: No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern. STZ-exposed mice showed a significant increase in pancreatic TBARS, MPO, IL-1β, and TNF-α levels, along with a significant decrease in FRAP value. Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

Conclusion: IMOD™ could ameliorate oxidative and immunological distresses of type-1 immunogenic diabetes but could not normalize blood glucose. Further studies are recommended to clarify the effects of IMOD™ on immunological factors to address whether this new agent could be applied in diabetes prevention or therapy.

No MeSH data available.


Related in: MedlinePlus

Non-fasting blood glucose changes in experimental groups. Difference in glucose value on days 7, 14, and 21 in D-IM and D-C compared with those of ND-C and ND-IM is significant at p < 0.01 (*). There was no difference between the diabetic group given IMOD™ and diabetic controls in blood glucose pattern
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298332&req=5

Figure 1: Non-fasting blood glucose changes in experimental groups. Difference in glucose value on days 7, 14, and 21 in D-IM and D-C compared with those of ND-C and ND-IM is significant at p < 0.01 (*). There was no difference between the diabetic group given IMOD™ and diabetic controls in blood glucose pattern

Mentions: After injection of STZ, blood glucose in both treated groups was raised. Though blood glucose did not attain the diabetic range (more than 200 mg/dl) after 7 days, all animals in both STZ-treated groups were diabetic when tested after 14 days. As shown in Figure 1, there was no difference between diabetic animals given IMOD™ and diabetic controls in blood glucose pattern. Also there was no significant difference in blood glucose between the two non-diabetic (IMOD™ alone and control) groups. IMOD™ treatment had no significant effect on blood glucose changes (Figure 1).


Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes.

Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M - Arch Med Sci (2010)

Non-fasting blood glucose changes in experimental groups. Difference in glucose value on days 7, 14, and 21 in D-IM and D-C compared with those of ND-C and ND-IM is significant at p < 0.01 (*). There was no difference between the diabetic group given IMOD™ and diabetic controls in blood glucose pattern
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298332&req=5

Figure 1: Non-fasting blood glucose changes in experimental groups. Difference in glucose value on days 7, 14, and 21 in D-IM and D-C compared with those of ND-C and ND-IM is significant at p < 0.01 (*). There was no difference between the diabetic group given IMOD™ and diabetic controls in blood glucose pattern
Mentions: After injection of STZ, blood glucose in both treated groups was raised. Though blood glucose did not attain the diabetic range (more than 200 mg/dl) after 7 days, all animals in both STZ-treated groups were diabetic when tested after 14 days. As shown in Figure 1, there was no difference between diabetic animals given IMOD™ and diabetic controls in blood glucose pattern. Also there was no significant difference in blood glucose between the two non-diabetic (IMOD™ alone and control) groups. IMOD™ treatment had no significant effect on blood glucose changes (Figure 1).

Bottom Line: In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated.No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern.Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Introduction: The aim of this study was to evaluate the effects and mechanisms of Setarud (IMOD™) as a multi-herbal medicinal formula on a mouse model of type 1 diabetes. METERIAL AND METHODS: Autoimmune diabetes was induced by multiple low-dose intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) for five consecutive days. IMOD™ was administered at an effective dose of 20 mg/kg/day for 21 days. After 21 days of treatment, the pancreases of the animals were separated and homogenized. In the pancreas tissue, the level of lipid peroxidation as thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α) were evaluated. Glucose changes were tested in the blood. Microscopic changes in the pancreas were followed by histological examinations.

Results: No significant difference was found between IMOD™ and diabetic control groups in blood glucose pattern. STZ-exposed mice showed a significant increase in pancreatic TBARS, MPO, IL-1β, and TNF-α levels, along with a significant decrease in FRAP value. Co-administration of IMOD™ significantly improved all the mentioned parameters disrupted by STZ administration except for blood glucose and histological changes.

Conclusion: IMOD™ could ameliorate oxidative and immunological distresses of type-1 immunogenic diabetes but could not normalize blood glucose. Further studies are recommended to clarify the effects of IMOD™ on immunological factors to address whether this new agent could be applied in diabetes prevention or therapy.

No MeSH data available.


Related in: MedlinePlus